AUTOLOGOUS THERAPEUTIC TUMOR VACCINE + IFN GAMMA IN OVARIAN CANCER
AUTOLOGOUS THERAPEUTIC TUMOR VACCINE + IFN GAMMA IN OVARIAN CANCER
批准号:
6265671
负责人:
RALPH Stuart FREEDMAN
金额:
$1.11万
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-12-01 至 1999-11-30
关键词:
cell proliferation clinical research clinical trial phase I combination cancer therapy cytotoxic T lymphocyte cytotoxicity dendritic cells drug administration rate /duration drug screening /evaluation histocompatibility antigens human subject human therapy evaluation injection /infusion interferon gamma interleukin 12 leukocyte activation /transformation neoplasm /cancer immunology neoplasm /cancer immunotherapy neoplasm /cancer vaccine neoplastic cell neoplastic process ovary neoplasms transforming growth factors tumor infiltrating lymphocyte vaccine development
中文摘要
本研究的长期目标是为卵巢癌开发有效的特异性肿瘤免疫疗法。许多临床前研究的结果表明,使用由共表达MHC抗原和B7.1共刺激因子的自体肿瘤细胞组成的治疗性疫苗在体内诱导抗肿瘤t细胞活化是可能的。以往的研究结果表明,卵巢肿瘤浸润淋巴细胞在某些情况下可能代表了体内被激活的淋巴细胞群,并且MHC参与了激活过程。在体内,树突状细胞或其他专业APC可能有助于t细胞的活化。我们已经在EOC患者的腹膜腔中发现了树突状细胞,但大多数这些细胞不表达CD80。因此,我们提出了一项实验性临床试验,以确定是否可以将感染了ALVAC-hB7.1的新鲜分离的EOC细胞IP注射,以及是否可以通过标准的评估方法将同样表达B7.1的自体肿瘤细胞IP注射在体内激活肿瘤特异性免疫。患者将接受3个剂量水平的ALVAC-B7.1感染细胞的治疗。ALVAC-B7.1感染的肿瘤细胞将只给予第一周。在第2周和第3周,将在ALVAC-B7.1感染的肿瘤细胞治疗之前使用两剂rIFN-g。3周的治疗相当于一个疗程。在没有进展的情况下,如果有肿瘤细胞,将给予进一步的疫苗和rIFN疗程。
英文摘要
The long-term goal of this study is to develop effective specific tumor immune therapy for ovarian cancer. Results from a number of preclinical studies suggest that it is possible to induce anti-tumor T-cell activation in vivo by the use of a therapeutic vaccine composed of autologous tumor cells that co-express MHC antigens and the B7.1 costimulatory factor. Results of previous studies suggest that ovarian tumor infiltrating lymphocytes may in some instances represent a population of lymphocytes that have been activated in vivo, and that the MHC is involved in the activation process. It is probable that dendritic cells or other professional APC's contribute to activation of T-cells in vivo. We have identified dendritic cells in the peritoneal cavity of EOC patients, but for the most part these cells do not express CD80. We have therefore proposed a pilot clinical trial to determine whether IP injection of freshly isolated EOC cells infected with the ALVAC-hB7.1 is feasible, and whether the IP injection of autologous tumor cells that also express B7.1 results in activation of tumor specific immunity in vivo by standard methods of evaluation. Patients will be treated at 3 dose levels of ALVAC-B7.1 infected cells. ALVAC-B7.1 infected tumor cells only will be given the first week. Two doses of rIFN-g will precede treatment with ALVAC-B7.1 infected tumor cells in weeks 2 and 3. The 3 week treatment equals a single course of treatment. In the absence of progression and if tumor cells are available, further courses of vaccine and rIFN will be administered.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Autologous therapeutic tumor vaccine + IFN-gamma
-
批准号:7043650
-
项目类别:
-
资助金额:$0.4万
-
财政年份:2004
-
负责人:RALPH Stuart FREEDMAN
-
依托单位:
Phase ii intraperitoneal rhIL 12
-
批准号:6515120
-
项目类别:
-
资助金额:$27.0万
-
财政年份:2001
-
负责人:RALPH Stuart FREEDMAN
-
依托单位:
Phase ii intraperitoneal rhIL 12
-
批准号:6340132
-
项目类别:
-
资助金额:$30.75万
-
财政年份:2001
-
负责人:RALPH Stuart FREEDMAN
-
依托单位:
B7.1 COSTIMULATION IN OVARIAN CANCER
-
批准号:6342153
-
项目类别:
-
资助金额:$14.84万
-
财政年份:2000
-
负责人:RALPH Stuart FREEDMAN
-
依托单位:
B7.1 COSTIMULATION IN OVARIAN CANCER
-
批准号:6046172
-
项目类别:
-
资助金额:$14.41万
-
财政年份:2000
-
负责人:RALPH Stuart FREEDMAN
-
依托单位:
IP PRIMING WITH RIFNG AND RIL 2 IN IP ADOPTIVE IMMUNOTHERAPY OF OVARIAN CANCER
-
批准号:6252254
-
项目类别:
-
资助金额:$1.67万
-
财政年份:1997
-
负责人:RALPH Stuart FREEDMAN
-
依托单位:
IP PRIMING WITH RIFNG AND RIL 2 IN IP ADOPTIVE IMMUNOTHERAPY OF OVARIAN CANCER
-
批准号:6281670
-
项目类别:
-
资助金额:$1.36万
-
财政年份:1997
-
负责人:RALPH Stuart FREEDMAN
-
依托单位:
OVARIAN CARCINOMA TIL TREATMENT AFTER IFN GAMMA/IL2
-
批准号:2107694
-
项目类别:
-
资助金额:$18.2万
-
财政年份:1994
-
负责人:RALPH Stuart FREEDMAN
-
依托单位:
OVARIAN CARCINOMA TIL TREATMENT AFTER IFN GAMMA/IL2
-
批准号:2107696
-
项目类别:
-
资助金额:$19.69万
-
财政年份:1994
-
负责人:RALPH Stuart FREEDMAN
-
依托单位:
OVARIAN CARCINOMA TIL TREATMENT AFTER IFN GAMMA/IL2
-
批准号:2107695
-
项目类别:
-
资助金额:$18.93万
-
财政年份:1994
-
负责人:RALPH Stuart FREEDMAN
-
依托单位:
OVARIAN CARCINOMA TIL TREATMENT AFTER IFN GAMMA/IL2
-
批准号:2429829
-
项目类别:
-
资助金额:$20.47万
-
财政年份:1994
-
负责人:RALPH Stuart FREEDMAN
-
依托单位:
IP PRIMING WITH RIFNG AND RIL 2 IN IP ADOPTIVE IMMUNOTHERAPY OF OVARIAN CANCER
-
批准号:6121100
-
项目类别:
-
资助金额:$1.51万
-
财政年份:--
-
负责人:RALPH Stuart FREEDMAN
-
依托单位:
AUTOLOGOUS THERAPEUTIC TUMOR VACCINE + IFN GAMMA IN OVARIAN CANCER
-
批准号:6309235
-
项目类别:
-
资助金额:$1.11万
-
财政年份:--
-
负责人:RALPH Stuart FREEDMAN
-
依托单位:
IP PRIMING WITH RIFNG AND RIL 2 IN IP ADOPTIVE IMMUNOTHERAPY OF OVARIAN CANCER
-
批准号:5224116
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:RALPH Stuart FREEDMAN
-
依托单位:--
海外基金